SCHEMBL17774939

SCHEMBL17774939

CCN(CC(=O)N(C)C)c1ccc(N)c(C(N)=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.43
▸ ALDH1A1 P00352 7/20 0.43
▸ MEN1 O00255 6/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ ATM Q13315 2/20 0.43
▸ S100B P04271 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ IKBKB O14920 1/20 0.38
▸ GFER P55789 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ PSMD14 O00487 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17774966 0.87 S100B (0.56) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL19788667 0.83 MAPT (0.43) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17774931 0.82 MAPT (0.42) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17774952 0.81 S100B (0.46) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17774929 0.80 S100B (0.45) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17774950 0.79 IKBKB (0.44) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17774935 0.78 IKBKB (0.42) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7675158 0.75 IKBKB (0.49) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17779227 0.75 IKBKB (0.38) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL11545057 0.74 S100B (0.56) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 — — US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION KRT18, ARSA, SQOR MAPT 2197/4885ALDH1A1 440/4885MEN1 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback